Skip to content
NBDC Human Database

No datasets in the cart.

Go to the cart

Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Research ID

hum0354-v1Release info

This page is a past version (v1). The latest version is v2.
Latest version (v2)

Research title

Analyses of circulating tumor cells from patients with advanced urogenital cancer

Research overview

Aims
In recent years, the detection and measurement of peripheral circulating tumor cells (CTC) has attracted attention as a useful method for diagnosing solid tumors, metastasis, recurrence, and prognosis. Unlike conventional tumor markers, cancer cells themselves are collected from the patient's peripheral blood, which is a means that enables a highly reliable diagnosis. In addition, the method has the advantage of being non-invasive and capable of time-series analyses. The purpose of this study is to collect CTCs from patients with advanced urogenital cancer, especially metastatic castration-resistant prostate cancer (CRPC), and analyze molecular expression abnormalities, and establish them as tumor markers for therapeutic effect determination and prognosis prediction.
Methods
CTCs are collected from CRPC patients receiving enzalutamide, docetaxel, or cabazitaxel.
Participants/materials
Patients with advanced metastatic CRPC undergoing drug treatment at Juntendo University Hospital
URL
N/A

Datasets

The list is the one this version published; each dataset's content is shown as it is now.

CartDataset IDType of dataAnalysis methodAccess criteriaDate published
NHA000174qRT-PCR
  • qRT-PCR (AR-V7)
Unrestricted-access2022-06-30

Data provider

Principal investigator
Masayoshi Nagata
Affiliation
Urology, Graduate School of Medicine, Juntendo University

Research projects

No research projects.

Grants

No grants.

Related publications

TitleDOIDataset ID
Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer
https://doi.org/10.1371/journal.pone.0226219 (opens in a new tab)
Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer
https://doi.org/10.1038/s41598-022-22854-1 (opens in a new tab)
Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases
https://doi.org/10.1038/s41598-023-35790-5 (opens in a new tab)